AB0878

COMPARISON OF CLINICAL FEATURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PATIENTS WITH SPONDYLOARTHROPATHIES WITH INFLAMMATORY BOWEL DISEASE

M. Uematsu1,2, K. Inui1, T. Okano1, Y. Yamada1, K. Manda1, Y. Sugikoka2, K. Mamoto1, T. Kikou3, H. Nakamura1. 1Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine; 2Department of Orthopedic surgery, Higashisumiyoshi morimoto hospital; 3Center for Senile Degenerative Diseases (CSDD), Osaka City University Graduate School of Medicine, Osaka; 4Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Wakayama, Japan

Background: Spondyloarthritis (SpA) is one of the representative comorbidities in patients with psoriasis (PsO) and inflammatory bowel disease (IBD) disease. However, the difference of clinical features between SpA due to PsO (PsA) and SpA due to IBD (IBD-SpA) are unclear.

Objectives: The purpose of this study is to compare the clinical features between patients with PsA and IBD-SpA.

Methods: Overall, 192 patients with PsO and 37 patients with IBD were included in this cross-sectional study. Clinical classification of PsA and IBD-SpA were performed according to the CASPAR1 criteria and ASAS criteria.2 Disease activity (DAS28-CRP), C-reactive protein (CRP), matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide antibody (ACPA), rheumatoid factor (RF), biologic disease modifying anti-rheumatic drugs (bDMARDs) use, and proportion of peripheral and axial disease were evaluated in patients with PsA and IBD-SpA.

Results: In this analysis, 74 patients were classified as PsA, 65 patients as PsO, 17 patients as IBD-SpA and 20 patients as IBD. The mean age was 56±14.7 years in PsA, 44.7±10.9 years in IBD (p=0.003). The mean BMI was 24.2±4.5 kg/m² in PsA, 23.7±3.2 kg/m² in IBD (p=0.18). DAS28-CRP was 3.26±1.6 in PsA, 4.02±1.5 in IBD-SpA (p=0.12). Axial SpA was observed in 4 (5.4%) in PsA, (29.4%) in IBD-SpA (p=0.01). Biologics were used in 29 (39.2%) patients in PsA, 17 patients as IBD-SpA and 20 patients as IBD. The mean age was 56.0±14.7 years in PsA, 44.7±10.9 years in IBD (p=0.003). The mean BMI was 24.2±4.5 kg/m² in PsA, 23.7±3.2 kg/m² in IBD (p=0.18). DAS28-CRP was 3.26±1.6 in PsA, 4.02±1.5 in IBD-SpA (p=0.12). Axial SpA was observed in 4 (5.4%) in PsA, 17 patients as IBD-SpA and 20 patients as IBD.

Conclusions: The clinical features between patients with PsA and IBD-SpA were compared. The patient with IBD-SpA was younger than patient with PsA and the prevalence of axial disease was more frequent in IBD-SpA.

REFERENCES:

Acknowledgements: We wish to thank Tomoko Nakatsuka for clinical assistant.

Disclosure of Interest: None declared


AB0879

FIBROMYALGIA IN PATIENTS WITHankylosing SPONDYLITIS: PREVALENCE AND RELATIONSHIP WITH DISEASE ACTIVITY

M. Sahli, O. Saidane, I. Mahmoud, A. Ben Tekaya, R. Tekaya, L. Abdelmoula. Rheumatology, Charles Nicolle Hospital, Tunis, Tunisia

Background: Spondyloarthritis (SpA) is an inflammatory rheumatic disease, characterised by spinal involvement, peripheral arthritis, or enthesitis with marked pain, stiffness, and fatigue. Fibromyalgia (FM) may be associated with SpA, and shares some common symptoms.

Objectives: We aimed to estimate the prevalence of FM in SpA and its influence on the assessment of SpA disease activity.

Methods: This single-centre cross-sectional study included consecutive patients with SpA according to the Assessment of SpondyloArthritis International Society criteria. The diagnosis was discussed at the 2010 American College of Rheumatology criteria. All patients underwent clinical evaluation of disease activity using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) and then compared in patients with and without FM.

Results: The study included 100 patients with SpA, 67 males and 33 females with a median age of 44.65 years. The prevalence of fibromyalgia was 20%. Patients fulfilling the criteria of FM presented a higher total BASDAI (5.86±1.97 vs. 3.15±1.99, p<0.01), higher ASDAS-CRP (3.43±1.13 vs. 2.41±1, p<0.01), higher ASDAS-VS (3.51±1.12 vs. 2.53±1.02, p<0.01) and poorer function scores (BASFI) (6.76±1.97 vs. 3.8±2.59, p<0.01).

Conclusions: FM is a frequent comorbidity in patients with SpA. In patients with SpA-FM, disease activity may be overestimated and this overestimation could lead to inappropriate treatment escalation.

REFERENCES:

Disclosure of Interest: None declared


AB0880

THE OBJECTIVE AUTOMATED MEASUREMENT OF FLUORESCENCE-SIGNAL INTENSITIES IN FLUORESCENCE-OPTICAL IMAGING TECHNIQUE DISCRIMINATES BETWEEN DISEASE ACTIVITY AND ITS RESPONSE IN ANTITNF TREATED PSORIATIC ARTHRITIS PATIENTS – AN INTERIMS ANALYSIS OF THE XPLORÉ-STUDY

M. Köhne1,2, S. Ohmdorf1, T. Rossmanith1, M. Sahli1, U. Henke1,2, A. Foldenauer2, T. Rossmanith2, M. Köhne1,2, S. Ohrndorf3, T. Rossmanith2, A. Foldenauer2, U. Henke1,2, CIRI, Goethe-University Frankfurt/Main; 2Clinical Research, Fraunhofer IAP, Frankfurt/Main; 3Rheumatology and Immunology, Universitätstramzdin Charité, Berlin; 4Rheumatology and Immunology, Universitätstramzdin Charité, Berlin; 5Rheumatology and Immunology, Universitätstramzdin Charité, Frankfurt/Main;

Background: Psoriatic arthritis (PsA) is a chronic inflammatory disorder combining joint and musculoskeletal inflammation. AntiTNF-therapy is induced after failure of NSAID and DMARD treatment. Up to 30–40% of the patients are primary not responding adequately to the induced biological therapy. In daily practice response is calculated by improvement of disease activity measured by clinical examination and calculated using composite indices. Feasible and robust biomarkers for prediction of response are missing.

Methods: Fluorescence optical imaging (FOI) is used as method for detection of changes in microvascularisation of the hands as potential marker for inflammation. ICG is injected as fluorescence agent, that is than stimulated by light and recorded by a specific camera system. An automated computer-based reading of the disease activity (DACT) is used as an objective method to display overall fluorescence-signals and their intensities. In a prospective multicentre study, the value of FOI in measurement of disease activity and its predictive value to discriminate responders in newly treated PsA patients is currently investigated in the XPLORÉ-study. This interim analysis investigates the value of baseline (BL) DACT to discriminate between responders (at least low disease activity (LDA) with DAS28 ≤3.2) and non-responders compared to standard clinical disease measurements (SJC, TJC, DAS28) over the 52 weeks observational period.

AB0888
ASSOCIATION OF RS12218 POLYMORPHISM IN SAA1GENE WITH LUMBAR SPINE SYNDESMOPHYES IN THE RUSSIAN ANKYLOSING Spondylitispopulation. A PILOT STUDY

M. Krivov1, S. Erdes1, A. Starkova, E. Samarkina, I. Guseva, N. Konvaltova, D. Varlamov1. I.V.A. Nasonova Research Institute of Rheumatology;1 All-Russian Research Institute of Agricultural Biotechnology, Moscow, Russian Federation

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease from the group of spondylarthritids (SpA). Earlier studies showed a correlation between SAA1 gene polymorphism, encoding serum amyloid A, and the development of secondary AA-amyloidosis in familial Mediterranean fever and rheumatoid arthritis in Caucasian and Asian populations. The Moriguchi et al (2005) study showed that the -13 T/C polymorphism in the gene S-flanking region (rs12218) is a better marker of AA-amyloidosis than mapping of polymorphisms in SAA1 exon 3 (SAA1.1 and SAA1.3). Data on rs12218 polymorphism contribution into predisposition to AS and its clinical phenotypes are very scarce. One of the clinical phenotypes, determining the severity of spine damage, is associated with presence of syndesmophytes (SM) in the lumbar (SMl), thoracic (SMt) and cervical (SMc) spine, confirmed by x-ray data.

Objectives: To study potential associations of rs12218 polymorphism in SAA1 gene with AS and phenotypes of radiographic progression, with the presence of SMl, SMt and SMc, and correlation with BASDAI, BASFI and ASAS indices.

Methods: rs12218 polymorphism was studied in 112 subjects: 47 AS patients (37 males and 10 females, mean age 40y, mean disease duration 213 weeks, mean age at onset 22y, positive for HLA-B27), and 65 healthy volunteers (controls). SAA1 gene rs12218 polymorphism was established. Mean BASDAI score was significantly higher in carriers of TC and CC genotypes compared to carriers of TT genotype (5.6±1.3 vs. 3.9±2.3,p=0.004). The mean BASFI scores in carriers of the respective genotypes were (6.1±2.3 vs 4.1±2.6, p=0.012). No significant correlation was found between rs12218genotypes and mean ASDAS score values.

Results: There was no significant difference between the patients and controls regarding age, sex, and body mass index. Clinical enthesopathy was detected in 36.7% of the SpA patients. Although ankle plantarflexion and dorsiflexion muscle velocities in all angular velocities were lower in the SpA patients, the difference did not reach statistical significance (p=0.05). All of the FAOS subscales were found to be significantly lower in the patients with SpA than in the controls (p<0.001). When the SpA patients were divided into two groups with clinical enthesopathy (n=22) and without clinical enthesopathy (n=38), there were significant differences between the groups regarding VAS pain, BASDAI, BASFI and SPARCC scores whereas there was no significant difference in muscle strength. Also, all FAOS subscale scores were significantly lower in the patients with clinical enthesopathy. Additionally, in the patients with SpA, while there were negative correlations between VAS pain, BASDAI, BASFI, SPARCC and FAOS subscale scores, there was a positive correlation between ankle muscle strength and FAOS scores (p<0.05).

Conclusions: We found that all the FAOS subscale scores were lower in the SpA patients and they were correlated with clinical findings. The results of our study indicate that even though there was not a significant decrease in the muscle strength, ADLs, sport and recreational activities, foot-related Ool are poorly affected in the SpA patients with Achill enthesitis.

Disclosure of Interest: None declared


ASSOCIATION OF RS12218 POLYMORPHISM IN SAA1GENE WITH SPONDYLOARTHRITIS: RELATIONSHIP WITH MUSCLE STRENGTH, ACTIVITIES OF DAILY LIVING AND QUALITY OF LIFE

Ö. Kuru1, B. Farisogullari, G. Atayk, A. Bilgic, D. Durnu, Physical Medicine and Rehabilitation, Ondokuz Mayis University Medical Faculty, Samsun, Turkey

Background: Enthesitis is a central feature of spondylarthritids (SpA). In SpA, muscle strength loss of the lower extremities are more commonly involved than those of the upper limbs, and the heel is the most frequent site. Investigation of peripheral enthesitis in SpA is based on clinical findings and/or imaging findings. The involvement of Achilles tendon may lead to pain, movement restrictions, decrease in muscle strength, and eventually a diminished quality of life (QoL).

Objectives: In the present study, we aimed to evaluate clinical enthesopathy and associated ankle muscle strength, activities of daily living (ADLs) and foot and ankle related QoL in the patients with SpA.

Methods: Sixty SpA patients fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for SpA (M/F=39/21) (35.6±9.85 years) and 50 healthy controls (M/F=32/18) (35.40±10.62 years) were enrolled in the study. Clinical enthesopathy was defined by the presence of at least one of the spontaneous pain, tenderness elicited by pressure, mobilisation and contraction against resistance of the corresponding tendons and local swelling of the enthes. Pain by visual analogue scale (VAS), disease activity by Bath Ankylos- spondylitis Disease Activity Index (BASDAI), enthesitis severity by SPARCC index was assessed in the patients. Isokinetic measurements of ankle dorsiflexion and plantarflexion were performed by the isokinetic dynamometer. The plantarflexion and dorsiflexion muscle velocities in all angular velocities were tested at 30° and 120°/sec angular velocities. Pain, other symptoms (stiffness, swelling, range of motion), ADLs, sport and recreational activities, and foot and ankle-related QoL were evaluated by the Foot and Ankle Outcome Score (FAOS) in which higher scores indicate lesser problems and/or functional limitations.

Results: There was no significant difference between the patients and controls regarding age, sex, and body mass index. Clinical enthesopathy was detected in 50.5% of the SpA patients. No association between this polymorphism and the presence of SMl, as well as BASDAI, BASFI scores and likelihood ratios of 3.89 (LQ+) and 0.28 (LQ-). The corresponding AUC value was 0.717 (95%CI:0.633–0.791). Compared to clinical disease measurements such as baseline DAS28, TJC or SJC, the DACT at BL was more discriminative to identify patients who attain LDA at W52.

Conclusions: This interim analysis of the XPLOR study shows promising data for the use of FOI as possible imaging biomarker for disease activity measure and prediction of response in PsA-patients treated with antiTNF-therapy. Baseline values evaluated using the automated computer-based reading of the fluorescence intensities with a cut-off of 4.55 are predictive for later achievement of DAS28 low-disease activity or remission within the treatment course. Data will be verified in a larger cohort of the XPLOR study.

Disclosure of Interest: M. Kühm Grant/support from: Pfizer Germany; S. Ohmorf: None declared. T. Rossmanith: None declared. A.Foldenauer: None declared. U. Henkemeyer: None declared. G. Schmitt: None declared. J. Berger Employee of: Xiralt GmbH; H. Burkhardt Grant/research support from: Pfizer Germany; F. Behrens Grant/research support from: Pfizer Germany